<DOC>
	<DOCNO>NCT00137436</DOCNO>
	<brief_summary>This multi-center , open-label , Phase 1/2 study SU011248 ( sunitinib malate , SUTENT ) combination docetaxel prednisone first-line treatment metastatic hormone-refractory prostate cancer ( mHRPC ) .</brief_summary>
	<brief_title>Study Of SU011248 In Combination With Docetaxel ( Taxotere ) And Prednisone In Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate Patients must progressive hormonerefractory prostate cancer ( HRPC ) : patient must undergo primary hormone treatment ( e.g . orchiectomy gonadotropin release hormone analog without antiandrogens ) . For patient receive antiandrogen therapy , disease progression must determine antiandrogen discontinuation Progressive disease base either nonmeasurable disease elevate PSA OR measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Prior thalidomide , antivascular endothelial growth factor ( VEGF ) therapy , VEGF receptor inhibitor , plateletderived growth factor ( PDGF ) receptor inhibitor antiangiogenic treatment kind include investigational therapy Prior chemotherapy Uncontrolled pain baseline , impend complication bone metastasis ( fracture and/or compression ) and/or presence urinary obstruction ( urinary retention , hydronephrosis ) History cardiac dysfunction , QT interval correct heart rate ( QTc ) &gt; 450 msec Central Nervous System ( CNS ) involvement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>First-line treatment metastatic hormone-refractory prostate cancer SUTENT combination docetaxel prednisone</keyword>
</DOC>